Comparative Pharmacology
Head-to-head clinical analysis: PLAVIX versus PLETAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLAVIX versus PLETAL.
PLAVIX vs PLETAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clopidogrel is a prodrug that is converted to an active metabolite by CYP450 enzymes. The active metabolite selectively inhibits the P2Y12 component of ADP receptors on the platelet surface, which prevents ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Cilostazol inhibits phosphodiesterase III (PDE3), increasing cAMP levels in platelets and vascular smooth muscle, leading to platelet inhibition and vasodilation.
75 mg orally once daily, with or without food. For acute coronary syndrome, a loading dose of 300 mg (or 600 mg for PCI) is given followed by 75 mg daily.
100 mg orally twice daily, administered at least 30 minutes before or 2 hours after meals.
None Documented
None Documented
Clopidogrel parent: ~6 hours; active thiol metabolite: ~30 minutes; terminal half-life of inactive metabolite(s): ~8 hours. Clinically, platelet inhibition persists for 5–7 days due to irreversible P2Y12 receptor binding.
Terminal half-life of cilostazol is approximately 11-13 hours; for active metabolites 3,4-dehydro-cilostazol (about 4-6 times more active) half-life is similar. Steady state achieved within a few days.
Renal: ~50% as inactive metabolites; biliary/fecal: ~50% as inactive metabolites.
Renal (approximately 77% as metabolites, <1% unchanged); fecal (approximately 18%)
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent